Under the agreement, the companies will share the U.S. responsibility to develop and commercialize Synta's lead compound STA-4783, a first-in-class, small-molecule, oxidative stress inducer, for metastatic melanoma, the most deadly form of skin cancer. (BioWorld Today) Read More
